Medical Device Safety Biosimilar Tariffs and USPTO Proposed Rule PTAB Proposed Rule - Restrict Use of IPR FY27 Appropriations: Domestic Production of Essential Medicines; Chemical-free Medical Devices Federal Procurement Preferences for Domestic Medicines Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC)
CMS Preference for Domestic Essential Medicines Net Elective Cost Policy: PBM Reform Through Bid Transparency
S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 2296: National Defense Authorization Act (NDAA) for Fiscal Year 2026 Biosimilar Tariffs and USPTO Proposed Rule PTAB Proposed Rule - Restrict Use of IPR Medical Device Safety FDA Streamlining FY27 Appropriations: Domestic Production of Essential Medicines; Chemical-free Medical Devices Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining FY27 National Defense Authorization Act - Domestic Production of Essential Medicines CMS Preference for Domestic Essential Medicines Federal Procurement Preferences for Domestic Medicines Ancillary Product Patent Reform Net Elective Cost Policy: PBM Reform Through Bid Transparency Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC) Procurement
Domestic Manufacturing CMS Preference for Domestic Essential Medicines Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC)
PTAB Proposed Rule - Restrict Use of IPR Patent Legislation Ancillary Product Patent Reform Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining
Tax Incentives for Domestic Manufacturing Tax Credits for Domestic Manufacturing of Essential Medicines